Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Key Stats

• Today's Range: $0.29 to $0.31
• 50-Day Range: $0.20 to $0.51
• 52-Week Range: $0.20 to $1.48
• Volume: 644,935 shs
• Average Volume: 1.75 million shs
• Market Capitalization: $75.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.83
• Consensus Rating: Moderate Buy

Adaptimmune Therapeutics Stock Analysis - MarketRank™

Adaptimmune Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 343rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adaptimmune Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adaptimmune Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adaptimmune Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adaptimmune Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adaptimmune Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.05% of the float of Adaptimmune Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adaptimmune Therapeutics has recently decreased by 15.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adaptimmune Therapeutics does not currently pay a dividend.

Dividend Growth

Adaptimmune Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.05% of the float of Adaptimmune Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Adaptimmune Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adaptimmune Therapeutics has recently decreased by 15.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.57

News Sentiment

Adaptimmune Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ADAP on MarketBeat in the last 30 days.

MarketBeat Follows

Only 3 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.74% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.

ADAP Stock Analysis - Frequently Asked Questions

How have ADAP shares performed this year?

Adaptimmune Therapeutics' stock was trading at $0.5387 at the start of the year. Since then, ADAP shares have decreased by 45.7% and is now trading at $0.2926.
View the best growth stocks for 2025 here.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings results on Monday, March, 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.09. The biotechnology company had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 74.15% and a negative net margin of 25.43%.
Read the conference call transcript.

When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Top institutional shareholders of Adaptimmune Therapeutics include Key Client Fiduciary Advisors LLC (0.06%). Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, Elliot Norry and John Lunger.
View institutional ownership trends.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 5/10/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADAP
• CIK: 1621227
• Web: www.adaptimmune.com
• Phone: 441235430000
• Fax: 44-12-3543-0001
• Employees: 490
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.83
• High Stock Price Target: $3.00
• Low Stock Price Target: $1.40
• Potential Upside/Downside: +525.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-113,870,000.00
• Net Margins: -25.43%
• Pretax Margin: -24.73%
• Return on Equity: -74.15%
• Return on Assets: -15.09%

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 3.85
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $178.03 million
• Price / Sales: 0.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 257,232,000
• Free Float: 224,051,000
• Market Cap: $75.27 million
• Optionable: Optionable
• Beta: 2.86